New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

WGSWW 11.07.2024

Full Press ReleaseSEC FilingsOur WGSWW Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - GeneDx Announces Preliminary 2024 Financial Results

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background

GeneDxindustry leading dataset from 46% non-white populations

STAMFORD, Conn.--(BUSINESS WIRE)--Nov. 7, 2024--GeneDx(Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration amongGeneDx, TheUniversity of Washington,Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children’s Hospital, was conducted on nearly 187,000 samples performed and across approximately 73,000 patients who received exome testing withGeneDx.

Findings uncover the diagnostic yield of exome sequencing for making an accurate and precise genetic diagnosis in children with rare diseases does not vary significantly between non-white and non-Hispanic white patients. Data from the study reveals that 46% of patients evaluated were non-white and within this group, the diagnostic rate for GeneDx’s exome testing when both parents were also tested remained consistently high at 27.1% compared to 27.4% for non-Hispanic white patients. These findings demonstrate disparities in precise genetic diagnosis are not due to diagnostic yields, but rather larger systemic structural barriers which may include complex workflows, costs, clinician shortages, unconscious biases and more.

“Our findings show that when people are tested, diagnostic rates among populations are comparable,” saidMike Bamshad, MD, FACMG, Professor of Pediatrics at theUniversity of Washingtonand Seattle Children’s Hospital. “Nevertheless, considerable disparities in access to testing remain. We, and our collaborators atGeneDx, are testing a variety of novel ways to simplify clinical workflows, increase provider readiness, and ultimately reduce barriers to genetic testing.”

“The growing utilization of GeneDx’s exome and genome testing enriches our unparalleled diverse dataset and creates a flywheel effect. With every test we complete, we deepen our understanding of disease-gene connections to inform more definitive diagnoses regardless of ancestral background. These are critical findings to ensure health equity within genomics,” said Dr.Paul Kruszka, MD, FACMG, Chief Medical Officer atGeneDx. “With similar diagnostic yields, the life-changing actionability of an accurate genetic diagnosis should be accessible to all andGeneDxis committed to breaking down systemic barriers and advocating for equitable access.”

The study was constructed using GeneDx’s industry leading diverse dataset of more than 700,000 clinical exome and genomes. The data was presented this week at theAmerican Society of Human Genetics(ASHG) annual meeting.GeneDxleverages its database as a critical tool to drive transformational care for pediatric patients and as the industry continues to look for strong evidence to expand the utilization and clinical utility of genome sequencing.

AboutGeneDx:

GeneDx(Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.GeneDxis at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visitwww.genedx.comand connect with us onLinkedIn,Facebook, andInstagram.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107395838/en/

Press@genedx.com

Investors@genedx.com

Source:GeneDx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com